Lab. of Diabetes and Metabolism

당뇨 및 대사질환 연구실

관련기사 바로가기
당뇨 및 대사질환 연구실

우리 연구실은 지방 조직 생물학과 당뇨병 및 대사 질환과 같은 엄청난 병리학을 연결하는 분자 경로를 이해하는 데 관심이 있습니다. 이러한 연구는 새로운 항 당뇨병 치료제를 개발하기위한 과학적 기초가 될 수 있습니다. 다음은 우리의 주요 연구 주제입니다.
1. 전신 포도당과 지질 대사를 조절하는 분자 메커니즘
2. 암 발생 조절
3. 신진 대사 질환 치료제 개발
Our lab is interested in understanding the molecular pathways that link adipose tissue biology to this staggering array of pathologies such as diabetes and metabolic diseases. These studies can be the scientific basis for developing novel anti-diabetic agents. Followings are our main research topics:
1. Molecular mechanism of regulating systemic glucose and lipid metabolism
2. Regulation of cancer development
3. Development of novel therapeutics for metabolic diseases

Major research field

Obesity, Diabetes, Metabolic Diseases, Inflammation, Non-alcoholic fatty liver disease

Desired field of research

Metabolic Diseases, Aging, Cancer metabolism, DNA damage repair

Research Keywords and Topics

· 당/지질 대사 조절 핵심 기전 규명 및 새로운 대사질환 치료제 개발
Understanding of molecular mechanisms of regulating glucose/lipid metabolism & development of novel therapeutics for metabolic diseases
· 백색지방의 갈색지방화를 활성화를 이용한 항비만 약물 개발
Development of novel anti-obesity drugs via browning of white adipocytes
· 암 생성, 활성 조절 분자 기전 연구 및 새로운 혁신 항암제 개발
Understanding the molecular mechanisms of cancer progression & development of novel anti-cancer drugs

Research Publications
MORE

· eLife; Lee Y.H. et al., (2022) Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA. 11:e70472
· Nucleic Acids Research; Ju et al., (2021) NSMF promotes the replication stress-induced DNA damage response for genome maintenance. 49
· Diabetes ; Choi, S. et al., (2016) PPARg antagonist Gleevec improves insulin sensitivity and promotes the browning of white adipose tissue. 65
· Genes and Development ; Choi, J. H., et al. (2014) Thrap3 docks on phosphoserine 273 of PPARg and controls diabetic gene programming. 28
· J. Biol. Chem.; Choi, S. S. (2014) A novel non-agonist PPARg ligand UHC1 blocks PPARγ phosphorylation by CDK5 and improves insulin sensitivity. 289
· Nature ; Choi, J. H., et. al. (2011) Potent Anti-Diabetic Actions of a Non-Agonist PPARg Ligand that Blocks Cdk5-Mediated Phosphorylation. Nature 477
· Nature ; Choi, J. H., et. al. (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARg by cdk5. 466

Patents

· Choi, J. H., Compositions, Kits, and Methods for Identification, Assessment, Prevention, and Therapy of Metabolic Disorders. PCT/US2011/021855
· Choi, J. H. Novel use of gleevec for treatment of diabetes mellitus and metabolic disease by specifically inhibiting phosphorylation at Ser273 of PPARg as PPARg agonist. 10-2014-0037199
· Choi, J. H. & Choi, S. Composition for degrading PPAR gamma comprising TRIM25 an active ingredient. 10-2072075

국가과학기술표준분류

  • LA. 생명과학
  • LA03. 발생·신경생물학
  • LA0302. 내분비생물학

국가기술지도분류

  • 건강한 생명사회 지향
  • 020300. 선도물질도출기술

녹색기술분류

  • 녹색기술관련 과제 아님
  • 녹색기술관련 과제 아님
  • 999. 녹색기술 관련과제 아님

6T분류

  • BT 분야
  • 보건의료 관련응용
  • 020211. 바이오신약 개발기술